NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
| NCT03277729 |
Immunotherapy After Chemotherapy in Treating Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma |
CD20 Positive|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular ... |
Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Cyclophosphamide
Drug: Fludarabine
Other: Laboratory Biomarker Analysis
Procedure: Leukapheresis |
Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) |
Phase 1
Phase 2 |
| NCT03277638 |
Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma |
Glioblastoma, Adult |
Drug: Pembrolizumab at 7 days prior
Drug: Pembrolizumab at 14 days post
Drug: Pembrolizumab at 35 days post
Procedure: Laser Interstitial Thermotherapy |
Case Comprehensive Cancer Center |
Phase 1
Phase 2 |
| NCT03277261 |
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) |
Relapsing Multiple Sclerosis (RMS) |
Biological: Ublituximab
Drug: Teriflunomide |
TG Therapeutics, Inc. |
Phase 3 |
| NCT03275597 |
Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition |
Non-small Cell Lung Cancer|Non-small Cell Lung Cancer Stage IV |
Drug: Durvalumab
Drug: Tremelimumab
Radiation: Stereotactic
Body Radiotherapy |
University of Wisconsin, Madison
AstraZeneca
National Cancer Institute (NCI) |
Phase 1 |
| NCT03274661 |
Pembrolizumab Activity in Patients With HR Competent and Deficient Tumors |
Solid Tumor, Adult |
Drug: Pembrolizumab 200 mg Q3W |
Baptist Health South Florida
Merck Sharp & Dohme Corp.
Miami Cancer Institute |
Phase 2 |
| NCT03274258 |
Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma |
Renal Medullary Carcinoma|Other Disorders of Kidney and Ureter |
Drug: Nivolumab
Drug: Ipilimumab |
M.D. Anderson Cancer Center
Bristol-Myers Squibb |
Phase 2 |
| NCT03274219 |
Study of bb21217 in Multiple Myeloma |
Multiple Myeloma |
Biological: bb21217 |
bluebird bio |
Phase 1 |
| NCT03277482 |
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer |
Recurrent Gynecological Cancer
Metastatic Cervical Cancer
Metastatic Ovarian Cancer
Metastatic Vaginal Cancer
Metastatic Vulvar Cancer... |
Drug: Durvalumab
Drug: Tremelimumab
Radiation: Radiation Therapy |
Dana-Farber Cancer Institute
AstraZeneca |
Phase 1 |
| NCT03277248 |
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2) |
Relapsing Multiple Sclerosis (RMS) |
Biological: Ublituximab
Drug: Teriflunomide |
TG Therapeutics, Inc. |
Phase 3 |
| NCT03274492 |
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma |
Diffuse Large B-Cell Lymphoma |
Drug: Polatuzumab Vedotin
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Vincristine Placebo
Drug: Prednisone
Drug: Polatuzumab vedotin Placebo |
Hoffmann-La Roche |
Phase 3 |
> 정보마당 > E-뉴스레터 > 전체
오시는 길
로그인
회원가입
